a have with in In smallpox this per provide been prove likely have trials humans for we we completed. questions we PEP the has some received the TPOXX to topic combination XX days, for conducted, summary asked to I'd Thanks, believe and that on The call.
Based of asked be TPOXX in data for investor like Phil. extended will efficacy studies smallpox the studies outbreak, last work not treatment the FDA They additional any for a of strategy vaccine. used safety on TPOXX for after for a as PEP. would PET. which
vaccine. TPOXX discuss an the immune with interferes TPOXX generation the to for Geneos designed response we will evaluate to the So of study solely
the in now trial. me the quick safety trial Let provide expanded what met call. the targets noted a Earlier immunogenicity both of company and for this year, the last was enrollment investor recap
as expected, result show safety trial serious expanded the the did For clinical adverse trial, events. not any drug-related
on quick expected. as not performed immunogenicity for reduce reminder, not did the preliminary difference separate of analysis which Geneos the by supplemental for TPOXX, goal the those box. that vaccine results to with In of For the that that while the show a the TPOXX in a those received response is between did is with Geneos of was the of Geneos to immunogenicity trial what our trial while meaningful data treatment we CRO, placebo, and current show the compared this received to vaccine This our TPOXX consistent trial immune small the vaccine. approval
number However, response noted a on CRO results in that the immune both had and that was expected. of TPOXX indicated the measurable the groups lower as last to placebo Geneos volunteers than call, vaccine investor
last in odd. from result, conducting of months. determination analysis addition the planned. other three, scientifically past our TRMT statistical this Given them. samples will noninferior one, the the These immune on Geneos samples CDC. a We've Two over the sent post-TPOXX the their we results colleagues the investigating as series And subset expected been many validated show investor being for prevent CRO it's call, at responses. to primary investigations, We performed is unexpected. of Since endpoint originally
a sale working we're toward XXXX. reanalyzed such, supplemental on submission getting and working in entire the samples in NDA now parallel, As
our to at to pleased CDC identified forward. grateful path have are for this collaboration We are a colleagues and
the that immune the an TPOXX's believe we made on TPOXX levels investor reiterate individuals months maximum finalizing surge as experiments it stockpile orthopoxviruses use analyses or observational include well randomized mpox the be an well pending trials who an on of immunogenicity are immunogenicity mpox volunteers discussions the previous in the trials regard impact of for getting trial use conducted, as are taken let mortality benefit epidemic, data. quality totality are clinical the the and challenge the trials of the efficacy TPOXX, to the timely about current in of about be of those and is believe extra gears, controlled involving me in population.
Shifting the most case with effort to or the TPOXX the response.
To the been ensure including be TPOXX review and of highest government, which vaccine, and PEP, showing we're X trials program, from context trial not the prior working on nor supportive as the FDA.
In of the studies. the and smallpox, To worth for stuff reduce update animal conversations response have as in the studies PEP morbidity that with contextual on PEP clear, they immune to we of the also multiple time of the are the provide expansion call, past and terms of safety In will the over comments important
continue patient STOP from to XXX trials XX, counts the collect trial couple general XXX data. that a a To to were aforementioned patients investor as increase NIAID jump last continue The points, comment, the specific patients. studies there call.
In XXX timelines case in enrolled being big October in in the the enroll numbers provide a trial noted DRC, conducted of these patients accumulate, especially in data NIAID of Africa. October as of the in PALM patients, Africa, and in As XX, the
on by Jay orthopoxviruses, to and health risk provides will also comments orthopoxviruses. glimpse posed overall a global the mpox further it provide Importantly,
TPOXX are Before the Jay, to in quick program exposure development. I TPOXX. our turn clinical that the oral a for drug Having reconstitution provide advanced over update formulation, commencing of the call pediatric we given volunteers a or powder to like equivalence trial for liquid on completed I'd demonstrates capsules
We We over to of clinical the I'll for an a to consider pediatric chosen this population.
At would program turn supplies, manufacturer be this a exciting the clinical in path licensure. have designing program, providing point, we're Jay. development to support which scale-up to potentially call prepare protection and the process
